Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLG0206 in Patients with PJI after TKA
NCT05137314Phase 1Completed
- Sponsor
- Peptilogics
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of zaloganan in periprosthetic joint infection (PJI) (2 arms), sponsored by Peptilogics. Primary endpoint: Percentage of participants with treatment-emergent adverse events at 1 year. Started Mar 2022; status: completed.
02
Drugs
zaloganan
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT05137314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137314.